Emily Dattilo
Shares of Sage Therapeutics were trading lower after the biopharmaceutical company said it plans to slash a third of the workforce.
Sage stock dropped 5.5% to $6.87 in Thursday trading, while the S&P 500 gained 0.3%.
The company on Thursday announced a reshuffling of its business operations to support the ongoing launch of zurzuvae in postpartum depression and focus pipeline development efforts leading up to a clinical study for dalzanemdor in Huntington's disease planned for later this year.
The news follows disappointing results earlier this month from a study to evaluate the effects of a dalzanemdor in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
The reorganization is expected to affect 165 employees (about 33% of the total workforce and about 55% of the company's research-and-development workforce), and includes changes to the leadership team. The move is planned to be substantially completed by the end of the fourth quarter.
It "is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth potential," according to a company press release.
Write to Emily Dattilo at emily.dattilo@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 17, 2024 09:47 ET (13:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。